Figure 2.
UBE2T-deficient MM cells are sensitive to DNA-damaging agents. (A-B) The MM cell lines MM1S (A) and U266 (B) were transduced with control shRNA (Sh-CT) or those targeting UBE2T (Sh-UBE2T) and cultured in the presence of indicated agents at the indicated doses. Cell viability was measured as described in “Methods.” Mean viability ± standard error of the mean is shown for 3 replicate experiments normalized to untreated controls. Western blots confirming UBE2T knockdown in MM1S and U266 cells are shown as panel IV in each figure. (C) Table showing 50% inhibitory concentration (IC50) values for the cytotoxicity of DNA-breaking agents in control and UBE2T-knockdown (UBE2T-KD) myeloma cells.

UBE2T-deficient MM cells are sensitive to DNA-damaging agents. (A-B) The MM cell lines MM1S (A) and U266 (B) were transduced with control shRNA (Sh-CT) or those targeting UBE2T (Sh-UBE2T) and cultured in the presence of indicated agents at the indicated doses. Cell viability was measured as described in “Methods.” Mean viability ± standard error of the mean is shown for 3 replicate experiments normalized to untreated controls. Western blots confirming UBE2T knockdown in MM1S and U266 cells are shown as panel IV in each figure. (C) Table showing 50% inhibitory concentration (IC50) values for the cytotoxicity of DNA-breaking agents in control and UBE2T-knockdown (UBE2T-KD) myeloma cells.

Close Modal

or Create an Account

Close Modal
Close Modal